Vivitrol (Injectable Naltrexone) (Alkermes Inc.) for outpatient treatment of alcohol dependence

Record ID 32010000947
Authors' objectives:

Alcohol dependence affects approximately 8 million people in the United States and it may be responsible for as many as 100,000 preventable deaths each year. The current mainstay of treatment for this disorder involves various psychosocial interventions such as addiction counseling, Alcoholics Anonymous and other self-help groups, and behavioral treatment such as cognitive behavioral therapy. Although these interventions are often effective, an estimated 40% to 70% of patients suffer relapse within 1 year after treatment. Some physicians believe that adding drug therapy to the other interventions would improve the likelihood of success. The drug naltrexone counteracts the pleasurable feelings experienced after drinking alcohol so it may help patients escape from alcohol dependence; however, naltrexone pills must be taken daily and many patients fail to do this.

Project Status: Completed
URL for project:
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Injections
  • Naltrexone
  • Outpatients
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
Contact Email:
Copyright: 2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.